Combination of chemotherapy and gefitinib as first-line treatment for patients with advanced lung adenocarcinoma and sensitive Egfr mutations: A randomized controlled trial

摘要: To explore the optimal treatment strategy for patients who harbor sensitive EGFR mutations, a head-to-head study was performed to compare chemotherapy and gefitinib in combination or with either agent alone as first-line therapy, terms of efficacy safety. A total 121 untreated advanced lung adenocarcinoma harbored mutations were randomly assigned receive combined pemetrexed carboplatin, plus alone. The progression-free survival (PFS) group (17.5 months, 95% CI, 15.3–19.7) longer than that (5.7 5.2–6.3) (11.9 9.1–14.6) group. (hazard ratios) HRs PFS versus groups 0.16 (95% 0.09–0.29, P < 0.001) 0.48 0.29–0.78, P = 0.003), respectively. overall response rate (ORR) therapy group, 82.5%, 32.5%, 65.9%, combinational resulted (OS) (HR 0.46, 0.016) 0.36, 0.001) Our finding suggested carboplatin could provide better benefits harboring mutations. This article is protected by copyright. All rights reserved.